JAZZ Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.2B
+13.0%
1.1B
-10.8%
1.2B
+6.4%
1.1B
+7.7%
1.0B
Cost of Revenue
116.4M
-13.2%
134.1M
-12.7%
153.5M
+19.1%
128.9M
+10.8%
116.3M
Gross Profit
1.1B
+16.8%
934.8M
-10.5%
1.0B
+4.7%
997.2M
+7.3%
929.4M
Operating Expenses
843.7M
+17.0%
721.0M
-8.7%
789.9M
-15.9%
939.7M
-41.8%
1.6B
R&D
207.5M
+5.9%
196.0M
-8.4%
213.9M
+7.9%
198.2M
+4.4%
189.9M
SG&A
389.2M
+10.3%
352.7M
-13.2%
406.2M
-23.4%
530.6M
+48.1%
358.4M
Operating Income
248.2M
+16.1%
213.8M
-16.0%
254.5M
+342.6%
57.5M
+108.4%
-686400000
EBITDA
504.3M
+27.6%
395.2M
-8.9%
433.7M
+55.9%
278.3M
-29.2%
393.0M
Net Income
192.8M
-34.2%
293.1M
+44.1%
203.5M
-19.1%
251.4M
+135.0%
-718500000
EPS (Basic)
$3.05
-35.5%
$4.73
+42.0%
$3.33
-19.6%
$4.14
+135.3%
$-11.74
EPS (Diluted)
$2.78
-37.2%
$4.43
+31.1%
$3.38
-17.2%
$4.08
+134.8%
$-11.74
Shares (Diluted)
69.4M
+5.0%
66.1M
+10.0%
60.1M
-2.4%
61.6M
+0.7%
61.2M
Jazz Pharmaceuticals (JAZZ) โ€” Financials